Interviews

Natasha Halasa, MD, MPH, Vanderbilt University Medical Center, discusses the most pressing diarrheal illness challenges and successful strategies physicians can use to reduce this burden in patients.

Amitkumar Mehta, MD, MBA, University of Alabama at Birmingham, notes the long-term data and potential curative effects of chimeric antigen receptor (CAR) T-cell therapy, while expressing optimism about bispecific therapy with ongoing evolution and the chance of significant patient responses.

Edward "Ted" Arrowsmith, MD, MPH, medical director for pathways at OneOncology and managing partner at Tennessee Oncology, highlights the need for trust between payers and providers, as well as finding balance in building consistent clinical pathways while prioritizing specific practice needs.

Industry stakeholders and patient advocacy groups are raising concerns with CMS due to high denial rates for non-invasive ventilators (NIVs) by Medicare Advantage plans.

Care in the fourth-trimester, when the birth has taken place and the mother and baby return home, is crucial for the well-being of the mother or the birthing person, Takiyah Durham, MBA, explains in an interview.

There is a lot of noise in the health care system, and oncologists need to collaborate and decide on common shared goals, said Lucy Langer, MD, MSHS, national medical director of oncology and genomics at UnitedHealthcare.

Leveraging technology intelligently can make the patient-doctor interaction much more seamless and connected, said Samyukta Mullangi, MD, MBA, medical director of oncology at Thyme Care, medical oncologist at Tennessee Oncology.

Regardless of kidney disease subtype, biomarkers can successfully ascertain risk of kidney disease progression, said Steven Coca, DO, MS, of the Icahn School of Medicine at Mount Sinai.

Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University's Feinberg School of Medicine, lists barriers to care for dermatology patients.

Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University's Feinberg School of Medicine, describes different methods dermatologists can use to treat atopic dermatitis (AD).

There is great value, both for clinical trials and clinical practice, in biomarkers that identify patients at greatest risk of developing chronic kidney disease (CKD) after acute kidney injury, explained Steven Coca, DO, MS, Icahn School of Medicine at Mount Sinai.

Robert Daly, MD, MBA, of Memorial Sloan Kettering Cancer Center, describes how new at-home treatment methods changed his delivery of care to patients with lung cancer.

Robert Gluckman, MD, MACP, from Providence Health Plan, discusses what he was most interested in hearing about at our Institute for Value-Based Medicine® event held in Newport Beach, California, on November 2.

Pregnancies for patients on dialysis are high risk and care by a multidisciplinary team is extremely important for a successful birth, explained Silvi Shah, MD, MS, FASN, assistant professor, Division of Nephrology and Hypertension, University of Cincinnati.

Data shows sodium-glucose cotransporter-2 (SGLT2) inhibitors are efficacious and can be used in almost all common kidney diagnoses, explained William G. Herrington, MD, MA, MBBS, Nuffield Department of Population Health, University of Oxford.

Sara Horst MD, MPH, FACG, discusses recent improvements she helped make to the Vanderbilt University Medical Center's (VUMC) digital health systems and what changes she plans to help implement in the future.

Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology, discusses unique challenges dermatologists face when treating patients with skin of color, who may present differently from White patients.

For patients with chronic kidney disease, dose adjustments for other medications requires coordination with other specialists to maintain treatment efficacy, explained Linda Awdishu, PharmD, FASN, professor and division head of clinical pharmacy at the University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences.

Smaller noncoding RNA is being used in clinical practice and as knowledge grows of long noncoding RNA, use of it should follow, explained Laura Denby, PhD, Kidney Research UK Senior Fellow, senior lecturer and principal investigator in the Centre for Cardiovascular Science at the University of Edinburgh.

Patient-Centered Oncology Care® (PCOC) 2023 has a diverse group of people coming in to discuss oncology, including payment reform and the future of oncology care, said Lalan Wilfong, MD, The US Oncology Network.

Sophia Humphreys, PharmD, MHA, BCBBS, discusses highlights of the Institute for Value-Based Medicine® (IVBM) event, held in partnership with Providence Health System, that recently took place in Newport Beach, California.

Amy Laughlin, MD, MSHP, of Orlando Health gave a preview of the topic she is presenting on at today's American Journal of Managed Care®’s Institute for Value-Based Medicine® event in New York City.

Afreen Shariff, MD, MBBS, Duke Cancer Institute, discusses the challenges and benefits of electronic consults (e-consults) for patients with cancer currently undergoing treatment who have a comorbidity history or who develop an endocrine system disorder because of treatment.

Kathi Mooney, PhD, RN, FAAN, of the University of Utah, gave a preview of "The Oncology Hospital at Home," the presentation she is giving at The American Journal of Managed Care®’s Institute for Value-Based Medicine® event on November 2 in New York City.

Brian Mullen, PhD, head of innovation and product at The Clinic by Cleveland Clinic, shares his expertise in providing easy-to-use digital health platforms for patients, while maintaining the cost-effectiveness of these innovations.

Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey, discussed cost savings that occurred so far from their collaborative pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health and also noted those they predict to occur as the program continues.

Leaders from Every Cure and Moonshots for Unicorns highlight their work toward finding treatments for rare diseases currently without a cure.

April Armstrong, MD, MPH, of University of California, Los Angeles, discussed how recent biologics advancements improved moderate-to-severe atopic dermatitis (AD) treatment.

Kristine Slam, MD, FACP, discusses the importance of genetic testing in male patients with breast cancer and why it’s important that all patients with breast cancer advocate for themselves.

Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey, provides an overview of their collaborative pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health, discussing the program's origin, objectives, and beyond.